Kirsch, Hannah M.

Background: Tranexamic acid (TXA) is widely used in craniosynostosis surgery to reduce blood loss. Although the efficacy of TXA administration has been documented in the literature, dosing in the perioperative setting is variable and without a standard protocol. The purpose of this study is to determine the efficacy of continuing TXA postoperatively for patients undergoing suturectomy for metopic or unicoronal synostosis. Methods: We conducted a retrospective cohort study evaluating the use of postoperative TXA infusion in patients undergoing suturectomy for metopic and unicoronal craniosynostosis. All patients received a TXA bolus of 10 mg/kg at the time of surgical prep, followed by a TXA infusion at 5 mg/kg/hour during the procedure. Patients undergoing suturectomy for metopic or unicoronal synostosis in 2020 to 2021 received postoperative TXA infusion at 5 mg/kg/hour for the first 4 hours after surgery. Following a protocol change in anemia management at the institution in 2022, patients undergoing this surgery in 2022 did not receive a postoperative TXA infusion. Chart review was performed, and mean hemoglobin values were compared between patients who received postoperative TXA and those who did not, with analyses stratified by suture involvement to determine the impact of the protocol change. Results: Twenty-eight patients met the inclusion criteria: 14 patients received postoperative TXA, and 14 patients did not. Both groups included 8 patients undergoing metopic suturectomy and 6 patients undergoing unicoronal suturectomy. For patients who underwent metopic suturectomy and received postoperative TXA, the mean preoperative hemoglobin was 11.4 g/dL, and on postoperative day 1 (POD1) was 8.1 g/dL. For patients who underwent metopic suturectomy and did not receive postoperative TXA, the mean preoperative hemoglobin was 11 g/dL and on POD1 was 9.2 g/dL ( P =0.27). The differences in mean preoperative and postoperative hemoglobin were not statistically significant between the 2 cohorts, P =0.15 and P =0.20, respectively. For patients who underwent unicoronal suturectomy and received postoperative TXA, the mean preoperative hemoglobin was 12 g/dL, and on POD1 was 8.7 g/dL. For patients who underwent unicoronal suturectomy and did not receive postoperative TXA, the mean preoperative hemoglobin was 11.4 g/dL and on POD1 was 9.1 g/dL ( P =0.36). The mean preoperative and postoperative hemoglobin were not statistically different between the 2 cohorts, P =0.42 and P =0.92, respectively. Hospital length of stay averaged 1 day across both cohorts. No patient received a postoperative blood transfusion. Conclusion: In patients undergoing suturectomy for metopic or unicoronal craniosynostosis, postoperative TXA infusion made no significant difference in postoperative hemoglobin levels, length of stay, or postoperative transfusion. Discontinuing postoperative TXA could potentially decrease monitoring needs and lower hospital costs.

Craniofacial surgery requires a multidisciplinary care approach in the perioperative period. In an effort to guide clinical decision making and standardize care, many institutions have implemented craniofacial surgical pathways, describing numerous variables to monitor and specific actions that must be completed by each involved discipline in the perioperative period. Adherence to these pathways can be challenging given the complexity of the protocol and the multiple disciplines involved. In an effort to improve adherence to our institution’s perioperative pathway, the authors implemented a quarterly, multidisciplinary craniofacial operative team meeting to review the pathway and improve the quality of care. The authors report results from a retrospective review of craniosynostosis suturectomy operations at a single site in the 2 years before and 2 years after the start of our team meeting to review perioperative care. A total of 141 operations were included (70 before the meeting and 71 after). Perioperative outcomes and adherence to our surgical pathway were compared. Following the start of our team meetings, there was a significant decrease in the time under anesthesia, patients requiring blood transfusion, and total hospital length of stay ( P <0.05). There was also improved adherence to the craniofacial pathway, with significantly more operations applying peripheral nerve blocks to all locations specified in our pathway with the proper drug contents ( P <0.05). Our findings suggest that craniofacial operative team meetings with a goal of reviewing the surgical pathway and discussing improvements in care plans with all involved providers can significantly improve adherence to operative pathways and surgical outcomes.